News ReleasesRSS
- Sep 06, 2024 Chugai Files in Japan for Additional Indication of Vabysmo for Angioid Streaks, a Leading Cause of Vision Loss
- Sep 02, 2024 PiaSky Approved in the EU as the First Monthly Subcutaneous Treatment for People with PNH
- Aug 28, 2024 Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer
- Aug 28, 2024 Transfer and Future Marketing of Secondary Hyperparathyroidism Drug “OXAROL for Injection” in Japan
- Aug 27, 2024 Roche’s Announcement regarding PiaSky (Approval in the EU for the Treatment of People with PNH)
What's NewRSS
- Jul 26, 2024 Script (including Q&A) for Conference on FY2024.12 Q2 Financial Results
- Jul 25, 2024 Conference on FY 2024.12 Q2 Financial Results
- Jul 25, 2024 Financial Results for Second Quarter of Fiscal Year 2024 (Jan-Jun 2024)
- Jun 27, 2024 Information Meeting on PiaSky®
- May 31, 2024 Annual Report 2023
Share price
Pick Up
About Chugai
-
- Company Outline
- Company Profile, Business Process, Directors & Officers, Organization.
-
- History of Chugai Pharmaceutical
- Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
- R&D
- Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
